Combination of cyclosporine A and methylprednisolone to treat pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome

Shinta Trilaksmi Dewi; Laily Noor Qomariah; Widya Khairunisa Sarkowi; Monika Puspitasari; Miya Khalidah; Marcella  Anggatama; Dwinanda Almira  Rizkiani; Kristiana Etnawati; Sri Awalia Febriana

doi:10.4081/dr.2023.9656

Authors

Shinta Trilaksmi Dewi
shinta.trilaksmi.d@ugm.ac.id
Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia. https://orcid.org/0000-0001-8972-4379
Laily Noor Qomariah Wates Government District Hospital, Kulon Progo, Yogyakarta, Indonesia.
Widya Khairunisa Sarkowi Faculty of Medicine, IPB University, Bogor, West Java, Indonesia. https://orcid.org/0000-0002-3974-5371
Monika Puspitasari Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia.
Miya Khalidah Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia. https://orcid.org/0000-0001-5730-9306
Marcella Anggatama Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia.
Dwinanda Almira Rizkiani Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia. https://orcid.org/0000-0003-3172-1962
Kristiana Etnawati Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia.
Sri Awalia Febriana Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia.

The treatment of epidermal necrolysis in pediatric patients remains a major challenge. Cyclosporine A has emerged as a promising therapy for epidermal necrolysis in adults; however, its efficacy in children is unclear. We present the case of a boy with Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome who was initially resistant to methylprednisolone monotherapy but improved after receiving the combination of cyclosporine A and methylprednisolone. Published reports on the use of cyclosporine A for pediatric epidermal necrolysis are also briefly reviewed.

Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina (Kaunas) 2021;57:1-15. DOI: https://doi.org/10.3390/medicina57090895

Hsu DY, Brieva J, Silverberg NB, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 2017;76:811-7.e4. DOI: https://doi.org/10.1016/j.jaad.2016.12.024

Abtahi-Naeini B, Dehghan MS, Paknazar F, et al. Clinical and epidemiological features of patients with drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Iran: different points of children from adults. Int J Pediatr 2022;2022:1-10. DOI: https://doi.org/10.1155/2022/8163588

Ramien M, Goldman JL. Pediatric SJS-TEN: Where are we now? F1000Res 2020;9:F1000 Faculty Rev-982. DOI: https://doi.org/10.12688/f1000research.20419.1

Liotti L, Caimmi S, Bottau P, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed 2019; 90:52-60.

Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol 2018;35:182-7. DOI: https://doi.org/10.1111/pde.13383

Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res 2020;9:F1000 Faculty Rev-612. DOI: https://doi.org/10.12688/f1000research.24748.1

Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2017;153:514-22. DOI: https://doi.org/10.1001/jamadermatol.2016.5668

Renfro L, Grant‐Kels JM, Daman LA. Drug‐induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989;28:441-4. DOI: https://doi.org/10.1111/j.1365-4362.1989.tb02502.x

Auyeung J, Lee M. Successful treatment of Stevens–Johnson syndrome with cyclosporine and corticosteroid. Can J Hosp Pharm 2018;71:272. DOI: https://doi.org/10.4212/cjhp.v71i4.2829

Yu R, Chen S, Pan Y, et al. Combined use of cyclosporine in the treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. J Dermatol 2022;49:629-36. DOI: https://doi.org/10.1111/1346-8138.16369

Coulombe J, Belzile E, Duhamel A, et al. Pediatric SJS/TEN subdued by a combination of dexamethasone, cyclosporine, and etanercept. J Cutan Med Surg 2019;23:547-50. DOI: https://doi.org/10.1177/1203475419861078

St John J, Ratushny V, Liu KJ, et al. Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol 2017;34:540-6. DOI: https://doi.org/10.1111/pde.13236

Alajmi A, Jfri A, Gomolin A, Jafarian F. A pediatric case of Stevens-Johnson syndrome/toxic epidermal necrolysis with rapid response to intravenous cyclosporine. JAAD Case Rep 2020;6:555-7. DOI: https://doi.org/10.1016/j.jdcr.2020.04.003

Szepietowski J, Wa̧sik F, Szybejko-Machaj G, Maj J. Toxic epidermal necrolysis successfully treated with cyclosporin: report of three cases. J Eur Acad Dermatol Venereol 1997;9:169-72. DOI: https://doi.org/10.1016/S0926-9959(97)00047-0

Aihara Y, Ito R, Ito S, et al. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone. Pediatr Int 2007;49:659-62. DOI: https://doi.org/10.1111/j.1442-200X.2007.02439.x

Sato S, Kanbe T, Tamaki Z, et al. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Int 2018;60:697-702. DOI: https://doi.org/10.1111/ped.13613

Zielińska M, Matusiak Ł, Golębiowski W, et al. Toxic epidermal necrolysis in an 8-year-old girl successfully treated with cyclosporin A, intravenous immunoglobulin and plasma exchange. Postepy Dermatol Alergol 2018;35:217-21. DOI: https://doi.org/10.5114/ada.2018.75247

Quintana-Castanedo L, Nieto-Rodríguez D, Rodríguez-Álvarez D, et al. Toxic epidermal necrolysis in a boy: successful treatment with cyclosporine A. Actas Dermosifiliográficas (Engl Ed) 2021;112:468-70. DOI: https://doi.org/10.1016/j.adengl.2021.02.013

Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation 2015;22:20-32. DOI: https://doi.org/10.1159/000362724

Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 2010;63: 925-46. DOI: https://doi.org/10.1016/j.jaad.2010.02.063

Ng QX, De Deyn M, Venkatanarayanan N, et al. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. J Inflamm Res 2018;11:135-42. DOI: https://doi.org/10.2147/JIR.S160964

Kumar P, Kanti Das N. Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality. Dermatol Online J 2016;22:13030. DOI: https://doi.org/10.5070/D32210032890

Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol 2013;79:686-92. DOI: https://doi.org/10.4103/0378-6323.116738

Weber LT, Armstrong VW, Shipkova M, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit 2004;26:415-24. DOI: https://doi.org/10.1097/00007691-200408000-00012

Dewi, S. T., Qomariah, L. N., Sarkowi, W. K., Puspitasari, M., Khalidah, M., Anggatama, M., Rizkiani, D. A., Etnawati, K., & Febriana, S. A. (2023). Combination of cyclosporine A and methylprednisolone to treat pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome. Dermatology Reports, 15(2). https://doi.org/10.4081/dr.2023.9656